FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn FDA's Overreach on Compounded Peptides Big news for peptides! In July, the FDA will meet to evaluate the most commonly used peptides for FDA authorized compounding. FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of